Skip to main content

Table 5 In vivo pharmacodynamic parameters of oxacillin products by multiple nonlinear regression (M-NLR).

From: In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin

OXACILLIN (OXA) PRODUCTS

N

SEM

ED50(mg/kg)

SEM

BD (mg/kg)

SEM

1LKD (mg/kg)

SEM

Experiment 1

        

OXA-BMS (innovator)

1.73

0.30

45.13

5.47

77.73

0.20

104.79

24.18

OXA-OPH

0.47

0.09

95.15

35.54

>750.00

-

>750.00

-

OXA-MEM

0.56

0.10

76.42

24.90

409.36

182.35

>750.00

-

OXA-SCA

0.56

0.10

72.66

23.71

390.13

172.68

>750.00

-

OXA-VIT

0.45

0.10

205.11

84.98

750.00*

373.73

>750.00

-

Experiment 2

        

OXA-BMS (innovator)

1.73

0.18

45.13

3.33

60.71

4.33

96.48

12.24

OXA-CAR

0.64

0.07

90.52

16.50

202.51

39.36

230.84

230.84

Experiment 3

        

OXA-BMS (innovator)

1.73

0.29

45.13

5.39

62.17

7.07

97.35

20.07

OXA-MEM

0.63

0.12

127.53

38.29

307.47

101.82

>750.00

-

OXA-OPH

0.55

0.10

128.00

42.18

526.98

225.98

>750.00

-

OXA-BLA

0.59

0.11

101.00

31.58

259.22

88.45

>750.00

-

Experiment 4

        

OXA-BMS (innovator)

1.73

0.21

45.13

3.96

49.23

3.83

88.41

17.53

OXA-QUIM

0.40

0.08

750.00

321.55

750.00*

287.80

750.00*

327.88

OXA-COL

0.58

0.09

221.34

54.59

287.58

70.52

750.00*

356.95

  1. Under this analysis, maximum effect (Emax) for all products is fixed to the innovator's (Emax= 5.42 log10 CFU/g).
  2. Abbreviators: N: Hill's slope; ED50: effective dose to reach 50% of Emax; BD: bacteriostatic dose; 1LKD: 1 log kill dose; SEM: standard error of the mean; Bold numbers: not statistically different from zero, invalid parameter. * Maximum dose used in the experiments.